Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal DoxorubicinPLDan Dynamic Randomized, Positive Control, Open, Multicenter Clinical Study

Next Previous
Trial Profile

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal DoxorubicinPLDan Dynamic Randomized, Positive Control, Open, Multicenter Clinical Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Adverse reactions

Most Recent Events

  • 02 Jul 2023 New trial record
  • 06 Jun 2023 Results assessing safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top